The role of histone deacetylase inhibitors in metastatic breast cancer

Bruna Zucchetti, Andrea Kazumi Shimada, Artur Katz, Giuseppe Curigliano

Research output: Contribution to journalReview articlepeer-review


Histone deacetylase inhibitors (HDACi) are a relatively new class of drug that plays an important role in the epigenetic and non-epigenetic regulation in cancer, inducing death, apoptosis and cell cycle arrest in cancer cells. Although HDACi are approved only for hematologic malignancies, there are several trials in the breast cancer setting with promising results. In this review, we summarize the latest studies with HDACi in breast cancer from the emerging data in the translational research until its possible applicability in the clinical practice.

Original languageEnglish
Pages (from-to)130-134
Number of pages5
Publication statusPublished - Feb 2019


  • Breast cancer
  • Epigenetic
  • Histone acetylation

ASJC Scopus subject areas

  • Surgery


Dive into the research topics of 'The role of histone deacetylase inhibitors in metastatic breast cancer'. Together they form a unique fingerprint.

Cite this